LKT Labs

Biochemicals for Life Science Research

Tolfenamic Acid

Tolfenamic Acid

Product ID T5846
Cas No. 13710-19-5
Purity ≥98%
Product Unit SizeCostQuantityStock
25 g $180.00 In stock
5 g $52.50 In stock
50 g $277.30 In stock
Bulk Quote

Quicklinks

Description

Tolfenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and anticancer chemotherapeutic activities; it inhibits COX-1 and COX-2. Tolfenamic acid inhibits leukotriene B4 (LTB4) production, degranulation, and migration in polymorphonuclear leukocytes. Tolfenamic acid also downregulates expression of cyclin D1, increases ER stress, and induces apoptosis in colorectal cancer cells, inhibiting tumor growth in vivo. Additionally, tolfenamic acid also decreases expression of VEGF, VEGFR1, HGFR/c-MET, survivin, Bcl-2, and Sp proteins in cellular models of colorectal cancer.

Product Info

Cas No.

13710-19-5
Purity

≥98%
Formula

C14H12ClNO2
Formula Wt.

261.70
Chemical Name

2-[(3-Chloro-2-methylphenyl)amino]benzoic acid
IUPAC Name

2-(3-chloro-2-methylanilino)benzoic acid
Synonym

Clotam, Tolfedine, Tolfine
Melting Point

207-207.5°C
Solubility

Slightly soluble in water; freely sol in buffers with pH >8.2
Appearance

Off White Crystal Powder, Odorless

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

T5846 MSDS PDF
Info Sheet

T5846 Info Sheet PDF

References

Pathi S, Li X, Safe S. Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors. Mol Carcinog. 2014 Feb;53 Suppl 1:E53-61. PMID: 23670891.

Zhang X, Lee SH, Min KW, et al. The involvement of endoplasmic reticulum stress in the suppression of colorectal tumorigenesis by tolfenamic acid. Cancer Prev Res (Phila). 2013 Dec;6(12):1337-47. PMID: 24104354.

Kankaanranta H, Moilanen E, Vapaatalo H. Comparison of in vitro effects of flunixin and tolfenamic acid on human leukocyte and platelet functions. Inflammation. 1993 Aug;17(4):417-25. PMID: 8406686.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • B3358

    Biochanin A

    Phytoestrogen, flavonoid found in clover, soy, and...
    ≥98%
  • E7578

    Estramustine

    Nitrogen mustard and estradiol derivative; microtu...
    ≥97%
  • M4652

    MLN8237

    AurKA inhibitor.
    ≥98%
  • N0160

    NAP Peptide

    Octapeptide derived from activity-dependent neurop...
    ≥95%
  • S8098

    SU-1498

    Tyrphostin; VEGFR inhibitor.
    ≥98%
  • N3323

    Nifuratel

    Nitrofuran derivative.
    ≥98%
  • H9863

    Hyperforin Dicyclohexylammonium

    Stable salt form of hyperforin, a compound found i...
    ≥97%
  • A9814

    AZD-4547

    FGFR inhibitor.
    ≥98%
  • G3554

    Ginsenoside Rb3

    Triterpene saponin found in species of Panax.
    ≥98%
  • A0962

    Adrenocorticotropic Hormone (1-4)

    Endogenous peptide hormone fragment, involved in s...
    ≥95%
  • H9718

    2-Hydroxyflutamide

    Non-steroid; AR antagonist.
    ≥98%
  • S7717

    Sterigmatocystin

    Mycotoxin produced by Aspergillus; carcinogen.
    ≥98%
  • U6857

    Urodilatin CCC

    ANP fragment, natriuretic peptide; Na+/K+ ATPase i...
    ≥98%
  • T2934

    Thiamphenicol Palmitate

    Chloramphenicol derivative; protein translation in...
    ≥98%
  • D3429

    Dihydrocytochalasin B

    Mycotoxin derivative; actin polymerization inhibit...
    ≥98%
  • H9815

    25-Hydroxyvitamin D3

    Vitamin D, calcitriol prodrug; VDR agonist.
    ≥98%
  • L8276

    Luteinizing Hormone Releasing Hormone

    Endogenous peptide hormone; GnRH agonist.
    ≥98%
  • S0830

    R-(+)-Schisandrin A

    Found in Schisandra.
    ≥98%
  • O9702

    Ozagrel Hydrochloride

    TxA2 synthase inhibitor.
    ≥98%
  • A4401

    ALAL

    Tetrapeptide used as a linker in drug development.
    ≥95%